IDXX trades 6.0% below Wall Street's consensus target of $716.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes IDXX achieves its forward estimates and maintains a stable P/E multiple of 45.5x. This scenario reflects the blended consensus of 23 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, IDEXX Laboratories, Inc. (IDXX) has a Wall Street consensus price target of $716.67, based on estimates from 23 covering analysts. With the stock currently trading at $676.04, this represents a potential upside of +6.0%. The company has a market capitalization of $53.33B.
Analyst price targets range from a low of $700.00 to a high of $740.00, representing a 6% spread in expectations. The median target of $710.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 13 analysts rating the stock as a Buy or Strong Buy,9 rating it Hold, and 1 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, IDXX trades at a trailing P/E of 51.7x and forward P/E of 45.5x. The forward PEG ratio of 3.18 reflects a premium valuation. Analysts expect EPS to grow -0.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $776.49, with bear and bull scenarios of $489.19 and $1023.10 respectively. Model confidence stands at 66/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ZTSZoetis Inc. | $33.3B | $79.40 | $84.75 | +6.7% | Hold | 12.8x | 32 |
 HSICHenry Schein, Inc. | $9.8B | $86.05 | $97.14 | +12.9% | Buy | 15.7x | 34 |
 ELANElanco Animal Health Incorporated | $12.9B | $25.74 | $26.67 | +3.6% | Buy | 22.7x | 22 |
 ANIPANI Pharmaceuticals, Inc. | $1.5B | $67.41 | $99.50 | +47.6% | Buy | 7.3x | 10 |
 NEOGNeogen Corporation | $2.6B | $11.76 | $13.50 | +14.8% | Buy | 35.3x | 11 |
 CHWYChewy, Inc. | $9.3B | $22.56 | $28.85 | +27.9% | Buy | 29.1x | 39 |
 DHRDanaher Corporation | $161.9B | $230.25 | $238.77 | +3.7% | Buy | 26.8x | 43 |
 BIOBio-Rad Laboratories, Inc. | $10.3B | $381.57 | $350.00 | -8.3% | Buy | 38.2x | 14 |
 TMOThermo Fisher Scientific Inc. | $258.2B | $694.76 | $694.27 | -0.1% | Buy | 27.5x | 43 |
 AAgilent Technologies, Inc. | $49.4B | $174.76 | $174.29 | -0.3% | Buy | 28.2x | 41 |
Quick answers to the most common questions about buying IDXX stock.
The consensus price target for IDXX is $716.67, close to the current price of $676.04 (6.0% implied move). Based on 23 analyst estimates, the stock appears fairly valued near current levels.
IDXX has a consensus rating of "Buy" based on 23 Wall Street analysts. The rating breakdown is predominantly bullish, with 13 Buy/Strong Buy ratings. The consensus 12-month price target of $716.67 implies 6.0% upside from current levels.
At a forward P/E of 45.4701x, IDXX trades at a premium valuation. The consensus price target of $716.67 (6.0% upside) suggests analysts may view current valuations as stretched.
The most bullish Wall Street analyst has a price target of $740 for IDXX, while the most conservative target is $700. The consensus of $716.67 represents the median expectation. Our quantitative valuation model projects a bull case target of $1023 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
IDXX is well covered by analysts, with 23 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 13 have Buy ratings, 9 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month IDXX stock forecast based on 23 Wall Street analysts shows a consensus price target of $716.67, with estimates ranging from $700 (bear case) to $740 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $776, with bear/bull scenarios of $489/$1023.
Our quantitative valuation model calculates IDXX's fair value at $776 (base case), with a bear case of $489 and bull case of $1023. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 66/100.
IDXX trades at a forward P/E ratio of 45.5x based on next-twelve-months earnings estimates compared to a trailing P/E of 51.7x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
IDXX appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $716.67 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
IDXX analyst price targets range from $700 to $740, a 6% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $716.67 consensus represents the middle ground. Our model's $489-$1023 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.